文献速递膀胱癌与上尿路尿路上皮癌

高危非肌层浸润性膀胱癌患者卡介苗灌注前门诊针刺治疗的1/2期随机临床试验

Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-04-22

本研究将接受诱导期卡介苗(BCG)灌注的高危非肌层浸润性膀胱癌患者按2:1随机分为针刺组(n=28)与标准治疗对照组(n=15),评估BCG灌注前门诊针刺的可行性、安全性和耐受性。针刺可在每次BCG灌注前顺利实施,无针刺相关不良事件或诱导期BCG中断;针刺组泌尿症状评分改善优于对照组,96%针刺患者认为针刺非常有帮助。

要点

  • 针刺组与对照组按2:1随机,分别为28例与15例,中位年龄70.3岁,76%为男性。
  • 针刺在每次BCG灌注前均成功实施,无针刺相关不良事件或诱导期BCG中断。
  • 针刺组中位泌尿症状改善9.5(IQR 0.0-19.0),对照组为0.0(IQR -14.3至7.1),p=0.02。

核心结论

  • 诱导期BCG治疗前针刺是可行且安全的。
  • 在该1/2期试验中,接受针刺的患者观察到泌尿功能评分改善。
  • 接受针刺的患者对治疗满意度高。

研究设计与样本

  • 1/2期随机临床试验,高危非肌层浸润性膀胱癌接受诱导期BCG的患者按2:1随机分为标准化针刺方案组与标准治疗对照组。
  • 共43例随机,针刺组28例,对照组15例;中位年龄70.3岁,76%为男性。
  • 可行性通过招募、留存和干预依从性评估;安全性通过医师报告的常见不良事件评价标准第5.0版及不良事件评估。

主要发现

  • 第7周随访调查完成率为93%;6例因疾病进展、难治性肉眼血尿或意愿退出。
  • BCG相关不良事件报告率:针刺组91% vs 对照组100%;疼痛28% vs 43%(p=0.34),泌尿症状62% vs 79%(p=0.31)。
  • 研究期间生活质量变化显示针刺组中位泌尿症状改善9.5(IQR 0.0-19.0)vs 对照组0.0(IQR -14.3至7.1),p=0.02。
  • 96%的针刺患者报告针刺非常有帮助或极其有帮助,91%会向其他患者推荐针刺。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量有限。
  • 单机构设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment-related dose-limiting dysuria and irritative bladder symptoms are common in patients receiving intravesical bacillus Calmette-Guérin (BCG) to treat non-muscle-invasive bladder cancer (NMIBC). Acupuncture has been shown to reduce pain and urinary urgency/frequency in other patient populations. OBJECTIVE: To evaluate the feasibility, safety, and tolerability of weekly in-clinic preprocedural acupuncture among patients receiving induction BCG. DESIGN, SETTING, AND PARTICIPANTS: Patients with high-risk NMIBC undergoing induction BCG were randomized 2:1 to a standardized acupuncture protocol (acupuncture) versus the standard-of-care control arm. INTERVENTION: In-office acupuncture prior to each BCG instillation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Feasibility was assessed via recruitment, retention, and intervention adherence. Acupuncture safety and tolerability were assessed via physician-reported Common Terminology Criteria for Adverse Events version 5.0 and adverse events (AEs). Secondary endpoints included BCG treatment adherence, patient-reported BCG-related toxicity, and bladder cancer-specific and generic (European Organisation for Research and Treatment of Cancer [EORTC]-QLQ-NMIBC-24 and EORTC-QLQ-NMIBC-C30) quality of life (QOL). Subjective assessments of acupuncture acceptability were performed through patient surveys. RESULTS AND LIMITATIONS: A total of 43 individuals were randomized 2:1 to the acupuncture (n = 28) versus control (n = 15) group. The median age was 70.3 yr, and 76% were male. Week 7 follow-up surveys were completed by 93%; six participants withdrew early due to disease progression, refractory gross hematuria, or preference. Acupuncture was delivered successfully prior to each BCG treatment, with no acupuncture-related AEs or interruptions to induction BCG. BCG-attributed AEs were reported by 91% acupuncture and 100% control individuals, including pain (28% vs 43%, p = 0.34) and urinary symptoms (62% vs 79%, p = 0.31). Comparing acupuncture patients with controls, change in QOL over the study period demonstrated greater improvements in median urinary symptoms (9.5, interquartile range [IQR] 0.0-19.0 vs 0.0, IQR -14.3 to 7.1; p = 0.02) among patients in the acupuncture arm. Of the acupuncture patients, 96% reported that acupuncture was "very/extremely helpful," and 91% would recommend acupuncture to other patients. Limitations include modest sample size and single-institution design. CONCLUSIONS: Acupuncture prior to induction BCG treatments is feasible and safe. In this phase 1/2 trial, improved urinary function scores were observed among patients undergoing acupuncture. Patients receiving acupuncture reported high degrees of satisfaction with treatments. PATIENT SUMMARY: We evaluated the safety and feasibility of delivering acupuncture in a urology clinic prior to weekly intravesical bladder cancer treatments with bacillus Calmette-Guérin (BCG) in a randomized controlled trial. We found that acupuncture could be delivered safely prior to weekly BCG instillations and that the use of acupuncture was associated with high patient satisfaction and a decrease in patient-reported urinary symptoms compared with usual care.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Psutka SP, Veleber S, Siman J, et al. Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024. PMID: 38653622. doi:10.1016/j.euo.2024.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。